ACC Research

I am only an ACC patient and not an expert at all.
The idea is simply to share the interesting articles I find and some good news to cheer us all up!

[ACC Research @ACCResearch1]

"Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022"

#adenoidcysticcarcinoma
https://t.co/htMBZTbuxc

[ACC Research @ACCResearch1]

"Detection & Characterization of Circulating Tumor Cells in #AdenoidCysticCarcinoma"

https://t.co/6l5r4XfBKG

[ACC Research @ACCResearch1]

"Increased retinoic acid signalling decreases lung metastasis in salivary #AdenoidCysticCarcinoma by inhibiting the noncanonical Notch1 pathway"

https://t.co/arA9cIigHT

[Rutgers Cancer Institute @RutgersCancer]

NOW OPEN @RutgersCancer: “Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.” #ClinicalTrial @RWJBarnabas

https://t.co/UmIJ9XXsEv

[ACC Research @ACCResearch1]

"Single-cell immune mapping of #AdenoidCysticCarcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype."

https://t.co/kKsA7CwDt9

[ACC Research @ACCResearch1]

"Low‑dose radiotherapy combined with immunotherapy for suboral adenoid cystic carcinoma with bilateral lung metastasis:
A case report and literature review"

https://t.co/ETvPhNUPvl

[ACC Research @ACCResearch1]

"Rivoceranib Elicits Promising Responses in #AdenoidCysticCarcinoma "

https://t.co/yDTPBdx7x3

[CancerNetwork® @CancerNetwrk]

Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma. #hncsm #ASCO22 | @ASCO

https://t.co/OBa0wzW6q0

[ACC Research @ACCResearch1]

"Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of #AdenoidCysticCarcinoma : a preclinical study"

https://t.co/B7wpKP7Bhl

[ACC Research @ACCResearch1]

"Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) #AdenoidCysticCarcinoma (ACC) harboring Notch activating mutations (Notchmut)."

https://t.co/voNvpcSm7C

[ACC Research @ACCResearch1]

"A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) #AdenoidCysticCarcinoma (ACC)."

https://t.co/J59m8SCCGj

[ACC Research @ACCResearch1]

"Surgical Navigation, Augmented Reality, and 3D Printing for Hard Palate #AdenoidCysticCarcinoma En-Bloc Resection: Case Report and Literature Review"

https://t.co/d09o1gaU4G

[ACC Research @ACCResearch1]

"Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic #AdenoidCysticCarcinoma : The SOLAR Trial"
https://t.co/eOrECk9ipM

[ACC Research @ACCResearch1]

"Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic #AdenoidCysticCarcinoma in a Phase 2 Trial"

https://t.co/X8ZsGA7q9O

[Rutgers Cancer Institute @RutgersCancer]

NOW OPEN @RutgersCancer: “Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.” #ClinicalTrial @RWJBarnabas

https://t.co/UmIJ9XXsEv

[ACC Research @ACCResearch1]

Trial - "Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma"

https://t.co/6l5r4Xxd9g

[Rutgers Cancer Institute @RutgersCancer]

NOW OPEN @RutgersCancer: “Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.” #ClinicalTrial #Carcinoma @RWJBarnabas #NationalCancerResearchMonth #NCRM22

https://t.co/UmIJ9XXsEv

[ACC Research @ACCResearch1]

https://t.co/xAYrJMz3g9

[Columbia Stem Cell Initiative (CSCI) @CSCIColumbia]

Congrats to @CSCIColumbia @columbiacancer PhD student Sara Viragova (Dalerba lab) awarded the 1st prize for Early Career Scientists by @jedirarecancer for her work on inhibitors of retinoid signaling as anti-tumor agents in Adenoid Cystic Carcinoma #cancer

[ACC Research @ACCResearch1]

"The anti-tumor effect of proteasome inhibitor MG132 for human #AdenoidCysticCarcinoma: correlate with the emerging role of Nrf2/Keap1 signaling pathway"

https://t.co/oCes7rX1rb

[ACC Research @ACCResearch1]

Trial "Axitinib for Disease Progression"
Eligible Conditions : #AdenoidCysticCarcinoma

https://t.co/b5phybPxg7